Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Breast Cancer Research : BCR|April 15, 2014
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trialMiguel Martin, Jan C Brase, Lourdes Calvo, et al.
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
BMC Cancer|October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testRalf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.
The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.
Neuron|November 11, 2022
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4Maud Gratuze, Johannes C M Schlachetzki, Ricardo D'Oliveira Albanus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Neuron|June 14, 2023
An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathologyPatrick W Sheehan, Collin J Nadarajah, Michael F Kanan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapySarah Minner, Malaika Enodien, Hüseyin Sirma, et al.
Pageof 21